Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep205 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2016

Effects of sex steroids on cardiovascular risk profile in female to male transsexuals with cross-sex hormone treatment

Velazquez Gloria Aranda , Porta Mireia Mora , Hanzu Felicia Alexandra , Vera Josep , Ortega Emilio , Halperin Irene

Introduction: In transsexualism, cross-sex hormone treatment (CHT) both improves and impairs several surrogate cardiovascular risk markers in female to male (FtoM). Few randomized trials on CHT with long follow-up and control group are available, and present evidence is inconsistent. We here assess changes in metabolic and cardiovascular risk after 12 months CHT compared with biological sex in FtoM GID.Methods: Prospective observational study, including ...

ea0041ep733 | Neuroendocrinology | ECE2016

Impaired innate immunity in Cushing’s syndrome: increase CD14+CD16++ monocytes

Velazquez Gloria Aranda , Lopez Cristina , Esteban Yaiza , Mora Mireia , Halperin Irene , Casals Gregori , Ensenat Joaquim , Hanzu Felicia Alexandra

Introduction: Chronic hypercortisolism is marked by an increased cardiovascular risk pattern. Atherosclerosis is a chronic inflammation that involves both innate and adaptive immunity. Glucocorticoids (GC) are immune-suppressors and adrenocorticotrophic hormone (ACTH) possesses immune-modulatory activities. GC and ACTH may act in atherothrombotic inflammatory pathways.Aim: To analyze the immune cells pattern in endogenous Cushing syndrome (CS) in order t...

ea0081ep106 | Adrenal and Cardiovascular Endocrinology | ECE2022

11-deoxycorticosterone producing adrenal hyperplasia as a very unusual cause of endocrine hypertension: case report and systematic review of the literature

Roca Queralt Asla , Simo Helena Sarda , Puertas Enrique Lerma , Hanzu Felicia Alexandra , Urgell Rull Eulalia , Perez Garcia Jose Ignacio , Youdale Susan Webb , Maso Ana Aulinas

11-deoxycorticosterone (DOC) is an aldosterone precursor synthesized from progesterone and converted to corticosterone in the adrenal cortex. DOC overproduction due to an adrenal lesion is a very rare cause of mineralocorticoid-induced hypertension. The objective of this study is to provide the most relevant clinical features that clinicians dealing with patients presenting with the hallmarks of hypertension due to DOC-producing adrenal lesions should be aware of. We report a ...

ea0032p341 | Developmental Endocrinology | ECE2013

Characteristics of the HIV positive transgender population of Catalonia

Patrascioiu Ioana , Lopez Carmen Quiros , Porta Mireia Mora , Velazquez Gloria Beatriz Aranda , Hanzu Felicia Alexandra , Gomez-Gil Esther , Godas Teresa , Rabinovich Irene Halperin

Introduction: Previous studies indicate a high prevalence of HIV infection in the transgender population and associate it with sexual risk behavior, psychiatrical and socio-economic problems. Anyway, few data are available regarding other factors. We assessed the prevalence of HIV and other associated characteristics in a transgender population of Catalonia.Methods: Cross-sectional study including 234 transsexuals that started follow-up in a reference ce...

ea0056p859 | Pituitary - Clinical | ECE2018

PROMPT: a prospective study to assess efficacy and safety of metyrapone in endogenous Cushing’s syndrome

Nieman Lynnette , Akinci Baris , Beckers Albert , Bolanowski Marek , Hanzu Felicia Alexandra , Mezosi Emese , Tonjes Anke , Bostnavaron Martine , Jaspart Amelie , Borensztein Pascale , Boscaro Marco , Scaroni Carla

Introduction: Metyrapone blocks cortisol production by inhibiting 11ß-hydroxylation of 11-deoxycortisol, the last step of cortisol synthesis. Based on observational retrospective studies published over more than 50 years metyrapone is approved for the treatment of endogenous CushingÂ’s syndrome (CS) in 14 European countries. PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern assay techniques.Desi...

ea0090rc6.3 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Lamas Cristina , Remon Pablo , Soto-Moreno Alfonso , Fajardo-Montanana Carmen , Biagetti Betina , Guerrero Fernando , Castro Marta Araujo , Mora Mireia , Hanzu Felicia Alexandra , Iglesias Pedro , Garcia Centeno Rogelio , Camara-Gomez Rosa

Introduction: Current guidelines propose temozolomide (TMZ) as the first-line chemotherapy for aggressive pituitary neuroendocrine tumors (PitNETs), but no clinical trials have been conducted and clinical experience in this context is limited.Patients and methods: A retrospective study of patients with aggressive pitNETs treated with TMZ was conducted by the members of the Neuroendocrinology Working Area of the Spanish Society of Endocrinology and Nutrit...

ea0063p1162 | Thyroid 3 | ECE2019

Microvascular blood flow measurements of the thyroid nodules by diffuse optics

Velazquez Gloria Aranda , Presti Giuseppe Lo , Contini Davide , Cortese Lorenzo , Mora Alberto Dalla , de Fraguier Sixte , Halperin Irene , Hanzu Felicia Alexandra , Pifferi Antonio , Rosinski Bogdan , Sekar Sanathana , Squarcia Mattia , Taroni Paola , Tosi Alberto , Weigel Udo M , Durduran Turgut , Mora Mireia

Background: The most common tool to test malignancy in the study of thyroid nodules (TN) is ultrasound and fine needle aspiration biopsy (FNAB). However, the sensitivity and specificity of the methods and the effectiveness in thyroid cancer are limited; therefore new methods to study thyroid nodules are required. In this way our goal is to introduce hybrid diffuse optical instruments that are capable to measure and discriminate altered microvascular blood flow, blood volume an...

ea0090ep730 | Pituitary and Neuroendocrinology | ECE2023

Precision medicine in acromegaly: results of the ACROFAST study

Puig-Domingo Manel , Marques-Pamies Montserrat , Gil Joan , Valassi Elena , Gimenez-Palop Olga , Hernandez Marta , Taibo Rocio Villar , Biagetti Betina , Villarroya Gemma Xifra , Simo-Servat Andreu , Zavala Roxana , Simon Inmaculada , Araujo-Castro Marta , Centeno Rogelio Garcia , Calatayud Maria , Miguel Federico Vazquez San , Vilarrasa N , Vert Isabel Salinas , Mora Mireia , Hanzu Felicia Alexandra , Novoa Maria Paz De Miguel , Pavon Isabel , Blanco Concepcion , Alvarez-Escola Cristina , Sampedro-Nunez Miguel Antonio , Jorda Mireia , Bernabeu Ignacio , Webb Susan , Marazuela Monica

Medical treatment of acromegaly is currently performed through a trial-error manner using somatostatin receptor ligands (SRLs) as first-line drugs. Average SRLs response is seen in 50% of cases; subsequent drugs are indicated following clinical judgement. Some biomarkers either before or after surgical failure have been reported to predict SRLs response, including intensity in T2 weighted MRI, short acute octreotide test (sAOT), and different molecules such as SST2 and E-cadhe...